Combined oral contraception and treatment of new coronavirus infection (COVID-19): drug interaction issues
Open Access
- 22 June 2021
- journal article
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 3,p. 30-39
- https://doi.org/10.37489/2587-7836-2020-3-30-39
Abstract
Combined oral contraception and treatment of new coronavirus infection (COVID-19): issues of drug interaction This article examines the interaction of combined oral contraceptives with drugs recommended in the treatment of new coronavirus infection (COVID-19) at the pharmacodynamic and pharmacokinetic levels, with an assessment of the effectiveness and safety of therapy for the female body.Keywords
This publication has 8 references indexed in Scilit:
- Response to 'Reply to Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy'Journal of Thrombosis and Haemostasis, 2022
- COVID-19 and clinical pharmacologyClinical pharmacology and therapy, 2020
- Gender Differences in Patients With COVID-19: Focus on Severity and MortalityFrontiers in Public Health, 2020
- Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 PandemicJournal of Invasive Cardiology, 2020
- COVID-19 and women’s health (literature review)Problemy reproduktsii, 2020
- Micronutrients supporting innate immunity against coronaviruses: results of a systematic computer analysis of publications on COVID-19 and human proteome antiviral proteinsФармакология & Фармакотерапия, 2020
- The importance of zinc in maintaining the activity of antiviral innate immunity proteins: analysis of publications on COVID-19Profilakticheskaya meditsina, 2020
- EFFECT OF COMBINED ORAL CONTRACEPTIVES ON WOMEN WITH MIGRAINEObstetrics, Gynecology and Reproduction, 2018